N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity
- 31 October 2003
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 100 (23) , 13674-13679
- https://doi.org/10.1073/pnas.1835612100
Abstract
The molecular and neuronal substrates conferring on clozapine its unique and superior efficacy in the treatment of schizophrenia remain elusive. The interaction of clozapine with many G protein-coupled receptors is well documented but less is known about its biologically active metabolite, N -desmethylclozapine. Recent clinical and preclinical evidences of the antipsychotic activity of the muscarinic agonist xanomeline prompted us to investigate the effects of N -desmethylclozapine on cloned human M1-M5 muscarinic receptors. N -desmethylclozapine preferentially bound to M1 muscarinic receptors with an IC 50 of 55 nM and was a more potent partial agonist (EC 50 , 115 nM and 50% of acetylcholine response) at this receptor than clozapine. Furthermore, pharmacological and site-directed mutagenesis studies suggested that N -desmethylclozapine preferentially activated M1 receptors by interacting with a site that does not fully overlap with the acetylcholine orthosteric site. As hypofunction of N -methyl- d -aspartate (NMDA) receptor-driven neuronal ensembles has been implicated in psychotic disorders, the neuronal activity of N -desmethylclozapine was electrophysiologically investigated in hippocampal rat brain slices. N -desmethylclozapine was shown to dose-dependently potentiate NMDA receptor currents in CA1 pyramidal cells by 53% at 100 nM, an effect largely mediated by activation of muscarinic receptors. Altogether, our observations provide direct evidence that the brain penetrant metabolite N -desmethylclozapine is a potent, allosteric agonist at human M1 receptors and is able to potentiate hippocampal NMDA receptor currents through M1 receptor activation. These observations raise the possibility that N -desmethylclozapine contributes to clozapine's clinical activity in schizophrenics through modulation of both muscarinic and glutamatergic neurotransmission.Keywords
This publication has 40 references indexed in Scilit:
- Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant miceNature Neuroscience, 2002
- Inhibition by two lavendustins of the tyrosine kinase activity of pp60F527 in vitro and in intact cellsPublished by Elsevier ,2002
- Glutamatergic Mechanisms in SchizophreniaAnnual Review of Pharmacology and Toxicology, 2002
- Allosteric binding sites on cell-surface receptors: novel targets for drug discoveryNature Reviews Drug Discovery, 2002
- Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective DisorderAmerican Journal of Psychiatry, 2002
- Transmembrane Domains 4 and 7 of the M1Muscarinic Acetylcholine Receptor Are Critical for Ligand Binding and the Receptor Activation SwitchPublished by Elsevier ,2001
- Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients.Journal of Pharmaceutical and Biomedical Analysis, 2001
- Effects of Desmethylclozapine on Fos Protein Expression in the Forebrain: In Vivo Biological Activity of the Clozapine MetaboliteNeuropsychopharmacology, 1998
- Clozapine is a potent and selective muscarinic M4 receptor agonistEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonistsEuropean Journal of Pharmacology: Molecular Pharmacology, 1993